Bernard B - Search Results

1

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M. Bernard B, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):173-80. doi: 10.1089/108497804323071940. Cancer Biother Radiopharm. 2004. PMID: 15186597

2

111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. Capello A, et al. Among authors: bernard b. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1288-95. doi: 10.1007/s00259-005-1877-x. Epub 2005 Jul 15. Eur J Nucl Med Mol Imaging. 2005. PMID: 16021448

3

From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging.

Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning EP, de Jong M. Forrer F, et al. Among authors: bernard b. Cancer Biother Radiopharm. 2007 Feb;22(1):40-9. doi: 10.1089/cbr.2006.353. Cancer Biother Radiopharm. 2007. PMID: 17627412

4

Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.

Verwijnen S, Capello A, Bernard B, van den Aardweg G, Konijnenberg M, Breeman W, Krenning E, de Jong M. Verwijnen S, et al. Among authors: bernard b. Cancer Biother Radiopharm. 2004 Jun;19(3):285-92. doi: 10.1089/1084978041425098. Cancer Biother Radiopharm. 2004. PMID: 15285875

5

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.

Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP. Breeman WA, et al. J Nucl Med. 2002 Dec;43(12):1650-6. J Nucl Med. 2002. PMID: 12468515 Free article.

6

Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Capello A, et al. J Nucl Med. 2003 Jan;44(1):98-104. J Nucl Med. 2003. PMID: 12515882 Free article.

7

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.

Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M. Breeman WA, et al. Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):312-5. doi: 10.1007/s00259-002-1054-4. Epub 2002 Nov 29. Eur J Nucl Med Mol Imaging. 2003. PMID: 12552352

8

Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.

Breeman WA, Mearadji A, Capello A, Bernard BF, van Eijck CH, Krenning EP, de Jong M. Breeman WA, et al. Int J Cancer. 2003 Apr 10;104(3):376-9. doi: 10.1002/ijc.10952. Int J Cancer. 2003. PMID: 12569562

9

Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.

Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Capello A, et al. Cancer Biother Radiopharm. 2003 Oct;18(5):761-8. doi: 10.1089/108497803770418300. Cancer Biother Radiopharm. 2003. PMID: 14629824

10

Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.

Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, Krenning EP. Breeman WA, et al. Nucl Med Biol. 2004 Aug;31(6):821-4. doi: 10.1016/j.nucmedbio.2004.03.008. Nucl Med Biol. 2004. PMID: 15246375

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

713 results

Search Page

Filters